Women and Lung Cancer Research and Preventive Services Act of 2025

HR2319, titled the Women and Lung Cancer Research and Preventive Services Act of 2025, was received in the Senate on April 22, 2026. It has been read twice and subsequently placed on the Senate Legislative Calendar under General Orders as Calendar No. 380. This signifies that the bill has completed initial Senate procedures and is now eligible for floor consideration, though no specific timeline for a vote is indicated. The bill's current status does not include any explicit authorization or appropriation of funds. Its focus is on directing research and preventive services, which typically involves policy directives rather than direct financial allocations within the bill itself. Any funding for such initiatives would likely be sought through subsequent appropriations bills or existing agency budgets, contingent on the bill's eventual passage into law. As the bill primarily focuses on research and preventive services, potential beneficiaries would include healthcare organizations, research institutions, and pharmaceutical companies involved in lung cancer diagnostics, treatment, and prevention. However, without specific funding mechanisms or direct procurement outlined in the current status, identifying specific tickers is not possible. The impact would be broad within the healthcare sector, potentially influencing research priorities and public health initiatives. No presidential actions directly amplify or conflict with this legislative activity. The recent presidential memoranda on domestic petroleum production and Air Force jet fighter training operations are unrelated to healthcare policy. The next legislative steps for HR2319 involve potential debate and a vote in the Senate. If passed by the Senate, it would then proceed to the President for signature.